We are live on ! Find out more
CDIO icon

Cardio Diagnostics
CDIO

30 hedge funds and large institutions have $49.6M invested in Cardio Diagnostics in 2022 Q1 according to their latest regulatory filings, with 30 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

2.7% more ownership

Funds ownership: 0% → 2.7% (+2.7%)

Holders
30
Holders Change
+30
Holders Change %
–
% of All Funds
0.47%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SCM
Saba Capital Management
New York
+$4.64M
2
KIM
Karpus Investment Management
New York
+$4.52M
3
PC
Periscope Capital
Ontario, Canada
+$4.28M
4
WAM
Weiss Asset Management
Massachusetts
+$3.59M
5
MSU
Mizuho Securities USA
New York
+$3.45M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
CCM
26
CAAS Capital Management
New York
$201K +$200K +677 New
WRBC
27
W.R. Berkley Corp
Connecticut
$196K +$195K +659 New
SSA
28
Schonfeld Strategic Advisors
New York
$99K +$98.4K +333 New
UBS Group
29
UBS Group
Switzerland
$3K +$2.96K +10 New
ASM
30
ATW SPAC Management
New York
$2.37K +$2.36M +8,000 New
1
2

CDIO Hedge Fund Activity: Q1 2022 in Review

30 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Cardio Diagnostics (CDIO) for Q1 2022, worth a combined $49.6M.

Buyers outnumbered sellers: 30 funds opened new CDIO positions and 0 closed out — a net gain of 30 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Saba Capital Management, opening a new position worth an estimated $4.64M.

  • 30 institutional investors held Cardio Diagnostics (CDIO) as of Q1 2022, up from 0 in Q4 2021.
  • Funds reported $49.6M of Cardio Diagnostics stock for Q1 2022.
  • 30 funds opened new Cardio Diagnostics positions in Q1 2022 and 0 closed out, a net change of +30 holders.
  • The largest Cardio Diagnostics buyer in Q1 2022 was Saba Capital Management, an estimated $4.64M added.

Based on aggregated 13F filings for Q1 2022.